Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-08-09
2011-08-09
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100
Reexamination Certificate
active
07993651
ABSTRACT:
Disclosed is an immunogen in sterile form suitable for administration to a human subject, the immunogen comprising: at least a portion of the gag protein of HIV, said gag protein being from an HIV clade or having a consensus sequence for one or more HIV clades, and comprising at least parts of p17 and p24; and a synthetic polypeptide comprising a plurality of amino acid sequences, each sequence comprising a human CTL epitope of an HIV protein, and wherein a plurality of HIV proteins are represented in the synthetic polypeptide, said CTL epitopes being selected to stimulate an immune response to one or more HIV clades of interest.
REFERENCES:
patent: 4629783 (1986-12-01), Cosand
patent: 4784941 (1988-11-01), Watanabe et al.
patent: 4808536 (1989-02-01), Chang et al.
patent: 4822606 (1989-04-01), Snyderman et al.
patent: 5134227 (1992-07-01), Chang et al.
patent: 5175097 (1992-12-01), Watanabe et al.
patent: 5175098 (1992-12-01), Watanabe et al.
patent: 5210181 (1993-05-01), Butman et al.
patent: 5328835 (1994-07-01), Watanabe et al.
patent: 5459238 (1995-10-01), McMichael et al.
patent: 5480967 (1996-01-01), McMichael et al.
patent: 5576421 (1996-11-01), Saito et al.
patent: 5639854 (1997-06-01), Sia et al.
patent: 5700635 (1997-12-01), McMichael et al.
patent: 5759769 (1998-06-01), Sia et al.
patent: 5759770 (1998-06-01), Guertler et al.
patent: 5817318 (1998-10-01), Sia et al.
patent: 5817754 (1998-10-01), Sia et al.
patent: 5861243 (1999-01-01), Dietrich et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 6111068 (2000-08-01), Zimmerman et al.
patent: 6271354 (2001-08-01), Srinivisan et al.
patent: 6395891 (2002-05-01), Karn et al.
patent: 1 088 889 (2001-04-01), None
patent: WO 91/04051 (1991-04-01), None
patent: WO 98/06429 (1998-02-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 00/15819 (2000-03-01), None
patent: WO 00/29008 (2000-05-01), None
patent: WO 00/39304 (2000-07-01), None
Hanke, T., et al., 1998, “Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice”, J. Gen. Virol. 79(1):83-90.
Korber, B., et al., eds., 1999, HIV Molecular Immunology Database, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, I-A-19-I-A-45, I-A-50-I-A-74, I-A-82-I-A-116, and I-A-121-I-A-138.
Kang, C. Y., et al., 1999, Development of HIV/AIDS Vaccine Using Chimeric Gag-Env Virus-Like Particles, Biol. Chem. 380:353-364.
Hanke, T., et al., 1998, DNA Multi-CTL Epitope Vaccines for HIV and Plasmodium falciparum: Immunogenicity in Mice, Vaccine 16(4):426-435.
Wagner, R., et al., 1992, Studies on Processing, Particle Formation, and Immunogenicity of the HIV-1 gag Gene Product: A Possible Component of a HIV Vaccine, Arch. Virol. 127:117-137.
Frankel, F. R., 1995, Induction of Cell-Mediated Immune Responses to Human Immunodeficiency Virus Type 1 Gag Protein by Using Listeria monocytogenes as a Live Vaccine Vector, J. Immunol. 155:4775-4782.
Bebbington, C. R. Expression of Antibody Genes in Nonlymphoid Mammalian Cells. Methods:Compan. Meth. Enzym. 2:136-145 (1991).
Berman, P. W. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with the recombinant glycoprotein gp120 but not gp160. Nature 345:622-625 (1990).
Cao, H. et al. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J. Virol. 71:8615-8623 (1997).
Dorrell, L. et al. Distinct Recognition of Non-Clade B Human Immunodeficiency Virus Type 1 Epitopes by Cytotoxic T Lymphocytes Generated from Donors Infected in Africa. J. Virol. 73:1708-1714 (1999).
Fultz, P. N. et al. Vaccine Protection of Chimpanzees Against Challenge With HIV-1-Infected Peripheral Blood Mononuclear Cells. Science 256:16871690 (1992).
Gold, David. Cent Gardes Meeting: Researchers Increasingly Optimistic About Prospects for AIDS Vaccine. IAVI Report: (Nov. 1999) at www.iavi.org/reports/60
ov-dec-1999-1.html.
Goulder, Philip J. R. et al. Differential narrow focusing of immunodominant human immunodeficiency virus Gag-specific cytotoxic T-lymphocyte responses in infected African and Caucasoid adults and children. J. Virol. 74:5679-5690 (2000).
Hanke, T. et al. Immunogenicities of intravenous and intramuscular administration of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J. Gen. Virol. 79:83-90 (1998).
Hanke, T. et al. Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal and tag-linked antigen. J. Gen. Virol. 73:653-660 (1992).
Hanke, T. and McMichael, A. J. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nature Med. 6:951-955 (2000).
Hanke, T. et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16:439-445 (1998).
Hanke, T. et al. DNA multi-CTL epitope vaccines for HIV and Plasmodium Falciparum: immunogenicity in mice. Vaccine 16:426-435 (1998).
Haynes, B.F. HIV vaccines: where we are and where we are going. Lancet 348:933-937 (1996).
Heilman, C. A. and Baltimore D. HIV vaccines-where are we going? Nature Med. Vacc. Suppl. 4:532-534 (1998).
Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD$ receptor and a neutralizing human antibody. Nature 393:648-659 (1998).
McMichael, A. J. and Hanke, T. Is an HIV vaccine possible? Nature Med. 5:612-614 (1999).
Moore, John P. et al. Inter-and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization gp120 antigenic serotypes. J. Virol. 70:427-444 (1996).
Rowland-Jones, S. L. et al. Cytotoxic T Cell Responses to Multiple Conserved HIV Epitopes in HIV-Resistant Prostitutes in Nairobi. J. Clin. Invest. 102:1758-1765 (1998).
Schneider J. et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of Malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 4:397-402 (1998).
Sidney, J. et al. Practical, biochemical and evolutionary implications of the discovery of HLA class supermotifs. Immunol. Today 17:261-266 (1996).
Trkola, A. et al. Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage. J. Virol. 72:1876-1885 (1998).
Thomson S. A. et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunology. 157:822-826 (1996).
Whittle, N. et al. Expression in COS cells of a mouse-human chimaeric B72.3 antibody. Protein Engineering 1:499-505 (1987).
Williams S. G. et al. Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res. 26:2120-2124 (1998).
Woodberry, T. et al. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8+ cytotoxic T-cell epitopes. J. Virol. 73:5320-5325 (1999).
Wyatt, R. et al. The antigenic structure of the HIV gp 120 envelope glycoprotein. Nature 393:705-711 (1998).
Nucleotide and Protein databases, EBI, UK GAG Polyprotein, Accession No. 036574 (1998) XP002170220.
Nucleotide and Protein databases, EBI,UK Polyprotein, Accession No. 089962 (1998) XP002170221.
C. Yong Kang et al., “Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles”, Biol, Chem., vol. 380, pp. 353-364, Mar. 1999.
R. Wagner et al., “Studies on Processing, Particle Formation, and Immunogenicity if the HIV-1 gag gene product: a possible component of a HIV vaccine”, Arch Virol (1992), vol. 127, No. 1 to 4, p. 117-137.
T. Hanke et al., “Immunogenicities of Intravenous and Intramuscular Administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 mice”, Journal of General
Hanke Tomas
McMichael Andrew
International AIDS Vaccine Initiative
Kowalski Thomas J.
Lu Deborah L.
Medical Research Council
Parkin Jeffrey
LandOfFree
Chimeric human immunodeficiency virus (HIV) immunogens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric human immunodeficiency virus (HIV) immunogens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric human immunodeficiency virus (HIV) immunogens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2752749